Featured Research

from universities, journals, and other organizations

Drug May Treat Previously Incurable Brain Cancer, Say Stanford Researchers

Date:
October 21, 2003
Source:
Stanford University Medical Center
Summary:
An old drug may have found a new role treating an incurable form of brain cancer called glioblastoma, according to preliminary research at Stanford University School of Medicine. The drug, called arsenic trioxide, increases the effectiveness of radiation therapy in mice with the disease.

STANFORD, Calif. - An old drug may have found a new role treating an incurable form of brain cancer called glioblastoma, according to preliminary research at Stanford University School of Medicine. The drug, called arsenic trioxide, increases the effectiveness of radiation therapy in mice with the disease. The researchers will present their work Oct. 22 at the American Society for Therapeutic Radiology and Oncology.

"Many brain cancers are incurable," said Susan Knox, MD, PhD, associate professor of radiation oncology, who led the study. "The use of arsenic trioxide with radiation may be one way to make the treatment more effective."

Arsenic trioxide has been approved by the U.S. Food and Drug Administration for use in treating a rare form of leukemia. It works in part by releasing damaging molecules called reactive oxygen species, or ROS, that destroy cancer cells. Shoucheng Ning, MD, PhD, a research associate working with Knox, thought the drug would release even higher levels of ROS when coupled with radiation therapy.

The team tested this idea in both the lab dish and in mice. In both cases, exposing glioblastoma cells to radiation within two hours of receiving a dose of arsenic trioxide amplified the effects of radiation treatment on its own.

The mice in this study had tumors formed by injecting human glioblastoma cells under the skin. In these mice, arsenic trioxide alone did not slow the tumor growth, and radiation alone delayed the tumor's growth for only 45 days. The combined treatment eliminated the tumor in four out of five mice and shrunk the tumor by 90 percent in the fifth mouse. The tumors had not begun growing again when the trial ended three months later.

Ning said that the arsenic trioxide dose the mice received is low enough that it would not be toxic in humans. "The concentration we used is already known to be achievable and is well tolerated in humans," he said.

"Based on these results we think the data are compelling enough to move forward with human trials," Knox said. She hopes to start preliminary human trials in conjunction with Iris Gibbs, MD, assistant professor of radiation oncology, by next year. The initial trials will be in recurrent glioblastoma and pediatric brain stem glioma, though Knox hopes to test the therapy in other cancers in the future.

Stanford University Medical Center integrates research, medical education and patient care at its three institutions - Stanford University School of Medicine, Stanford Hospital & Clinics and Lucile Packard Children's Hospital at Stanford. For more information, please visit the Web site of the medical center's Office of Communication & Public Affairs at http://mednews.stanford.edu.


Story Source:

The above story is based on materials provided by Stanford University Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Stanford University Medical Center. "Drug May Treat Previously Incurable Brain Cancer, Say Stanford Researchers." ScienceDaily. ScienceDaily, 21 October 2003. <www.sciencedaily.com/releases/2003/10/031021061411.htm>.
Stanford University Medical Center. (2003, October 21). Drug May Treat Previously Incurable Brain Cancer, Say Stanford Researchers. ScienceDaily. Retrieved July 25, 2014 from www.sciencedaily.com/releases/2003/10/031021061411.htm
Stanford University Medical Center. "Drug May Treat Previously Incurable Brain Cancer, Say Stanford Researchers." ScienceDaily. www.sciencedaily.com/releases/2003/10/031021061411.htm (accessed July 25, 2014).

Share This




More Health & Medicine News

Friday, July 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com
Condemned Man's US Execution Takes Nearly Two Hours

Condemned Man's US Execution Takes Nearly Two Hours

AFP (July 24, 2014) America's death penalty debate raged Thursday after it took nearly two hours for Arizona to execute a prisoner who lost a Supreme Court battle challenging the experimental lethal drug cocktail. Duration: 00:55 Video provided by AFP
Powered by NewsLook.com
Can Watching TV Make You Feel Like A Failure?

Can Watching TV Make You Feel Like A Failure?

Newsy (July 24, 2014) A study by German researchers claims watching TV while you're stressed out can make you feel guilty and like a failure. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

    Health News

      Environment News

        Technology News



          Save/Print:
          Share:

          Free Subscriptions


          Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

          Get Social & Mobile


          Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

          Have Feedback?


          Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
          Mobile: iPhone Android Web
          Follow: Facebook Twitter Google+
          Subscribe: RSS Feeds Email Newsletters
          Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins